ARCHIVES

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

In this 12-page issue: Moonlighting by NCI and FDA scientists conflicted with CRADA work, House Subcommittee on Oversight and Investigations says.

May 21, 2004

Brown’s appointment may Be Delayed Until After Jan. 20

January 14, 1977

Interest Picks Up In SBIR, NCI May Not Gave To Face Choice of Giving Money Back Or Paying to 500 Level

November 23, 1984

Seven Seats Open Up On NCAB

January 17, 1986

BSA, BSC Approve Concept for NCI Scholars Program

March 7, 1997

Five Investigations Probe NIH Radiation Contamination

November 17, 1995